Return to previous page


ACE-083 is a myostatin inhibitor (GDF-8 – a substance which can decelerate and restrain muscle growth). By blocking myostatin, ACE-083 supports faster, greater and more efficient muscle gain.

Moystatin (GDF-8 = Growth differentiation factor 8) is a protein that in humans is encoded by the MSTN gene. Moystatin (GDF-8) belongs to the GDF proteins family that inhibits muscle growth. The moystatin protein is produced primarily in the skeletal muscle cells, circulates in the blood and acts on muscle tissues – it slows down the stem cells differentiation (and inhibits new muscle mass production). However, an exact mechanism of action remains unknown.

Myostatin and its related gene were discovered in 1997. Genetics doctors Dr. Se-Jin Lee and Alexandra McPherron found out that the cause of abnormal extra-huge muscles of the two breeds of cattle, Belgian Blue and Piedmontese, had the damaged myostatin genes (this muscle feature of these cattle breeds is known as “double muscling”).

They unnaturally produced a strain of mutant mice that lacked myostatin. As a result, these mutant mice had approximately twice as much musculature as normal mice. These mice were subsequently named as “mighty mice”. Mutation of the moystatin gene results in an inability of the body to produce its own myostatin and then myostatin cannot inhibit the muscle growth.

Afterwards, these mutations started to be used for breeding new muscular cattle breeds. Genetic mutations of the myostatic gene were observed also in a breed of racing dogs closely related to greyhounds (Whippet). Individuals with the myostatin gene mutation were apparently more capable runners and they featured different overall appearance. It is not disputed that animals lacking myostatin or animals treated with doping substances that block the myostatin activity (such as, e.g. Follistatin) have significantly larger muscles. Even a 20% reduction in moystatin levels has a great effect on the muscle development.

In 2004, a German boy was diagnosed with a mutation in both copies of the myostatin-producing gene, making him considerably stronger than his peers. As the boy is growing, he is becoming stronger than his peers. The lack of myostatine has not yet reflected on his overall health condition. Doctors will have to continue to observe him closely just in case, he could develop hypertrophy of the vital organs (e.g. heart hypertrophy). His mother, a former female sprinter, has a mutation only in one copy of the gene. People with a mutation in both copies of the MSTN gene in each cell (homozygotes) have significantly increased muscle mass and strength than common people; therefore, they appear stronger than the standard level. People with a mutation in one copy of the MSTN gene in each cell (heterozygotes) also have increased muscle bulk, but to a lesser degree.

In 2013, Acceleron Pharma published results of a human study, in which 48 healthy women aged from 45-75 were given a single injection containing 0.02, 0.05, 0.1, 0.3, 1 or 3 mg ACE-083 per kg bodyweight. The single injection did lead to muscle growth. The 3 mg/kg dose led to an increase in muscle volume by 5 percent, it boosted lean body mass by 3 percent and additionally, it seemed to also reduce fat mass. The injection reduces also the leptin concentration. This would suggest that ACE-083 decreases actively the fat mass level. ACE-083 remained in their body through several weeks after administration and the half-life was estimated to 10-15 days.

The myostatin inhibition leads to muscular hyperplasia (growth of new muscle fibres) and significantly larger hypertrophy (growth and volume increase of already existing muscle fibres). From this point of view, those products truly have a great future potential for sportsmen who aim at the increase of muscle growth.

Supposedly, one of the best bodybuilders ever – the phenomenal Flex Wheeler – has a lack of myostatin, as well.



ACE-083 causes a huge increase in muscle mass and muscle strength that can supposedly compete over even the most efficient hardcore volume steroids, such as Oxymetholone.

Taking ACE-083 results in the fast and almost immediate increase of muscle hardness

ACE-083 promotes fat burning



Even a small dose of ACE-083 of 1 mg can have a substantial effect. Sportsmen taking 1 mg of ACE-083 once a week over the period of 3-4 weeks report nearly an immediate increase in the muscle hardness and the rapid growth of muscle mass and strength to an extent exceeding even the most efficient hardcore volume anabolic-androgenic steroid, such as Oxymetholone!

Another dosing option is to start with the dose of 200 mcg of ACE-083 per day and to increase the dose every week by 100 mcg, whereas the treatment cycle should last again 3-4 weeks.

Once a cycle with ACE-083 is completed, a break in the duration of two weeks is recommended. Note: Note that ACE-083 is a very vulnerable substance! Therefore, it should be administered as a single. When combined with other peptides (mixed into the same syringe), it can be damaged. You should not even shake the bottle with the content of the reconstituted ACE-083 and even a little more rigorous injection of an antibacterial solution into the vial with ACE-083 may cause damage of peptides in the upper layer of the powder. THE POSSIBLE SIDE EFFECTS: In clinical studies performed by Acceleron Pharma on a sample of adult males (volunteers), some study participants treated with ACE-083 experienced minor nose and gum bleeding and dilation of blood vessels in the skin. The majority of these side effects completely resolved once the treatment with ACE-083 was completed or discontinued.


All products listed and provided through Xtremepro are intended for research purposes only. We do not promote the personal use of these products. Products provided by Xtremepro are not intended for use in food products or as any type of drug. Our products are not intended to treat, prevent, mitigate or cure any disease or medical condition.

Weight 0.830 kg

Box, Vial


There are no reviews yet.

Be the first to review “ACE-083 (Untagged) 2mg”